Eyeworld Daily News

2017 ASCRS Los Angeles Daily Sunday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/820839

Contents of this Issue


Page 2 of 112

Marks designated ® and ™ are owned by Shire or an affi liated company. ©2016 Shire US Inc. Lexington, MA 02421 S24435 11/16 IIMPROVEMENT SIGN & SYMPTOM The only prescription eye drop FDA-approved to treat both the signs and symptoms of Dry Eye Disease Xiidra improved patient-reported symptoms of eye dryness and improved signs of inferior corneal staining. So help patients get to know Xiidra. Check it out at Xiidra-ECP.com Four randomized, double-masked, 12-week trials evaluated the effi cacy and safety of Xiidra versus vehicle as assessed by improvement in the signs (measured by Inferior Corneal Staining Score) and/or symptoms (measured by Eye Dryness Score) of Dry Eye Disease (N=2133). The safety of lifi tegrast was evaluated in 5 clinical studies. 1401 patients received at least one dose of lifi tegrast (1287 of which received Xiidra). The most common adverse reactions (5-25%) were instillation site irritation, dysgeusia, and reduced visual acuity. Indication Xiidra ® (lifi tegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). Important Safety Information In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface. Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. Safety and effi cacy in pediatric patients below the age of 17 years have not been established. Please see the adjacent page for Brief Summary of Safety Information and visit Xiidra-ECP.com for Full Prescribing Information.

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2017 ASCRS Los Angeles Daily Sunday